Krystal Biotech to Present Phase 1 Data for KB407 Gene Therapy in Cystic Fibrosis
核心洞察
Krystal Biotech will announce interim clinical results from the highest dose cohort of its Phase 1 CORAL-1 study evaluating KB407 gene therapy in cystic fibrosis patients on January 8, 2026.
The update will include molecular assessments of KB407 transduction and wild-type CFTR (搜索) protein expression following inhaled administration of the investigational therapy.
The CORAL-1 study is a multi-center, dose escalation Phase 1 trial designed to evaluate the safety and efficacy of KB407 in patients with cystic fibrosis.
Krystal Biotech announced it will host an investor conference call on January 8, 2026, at 4:30 pm ET to disclose interim clinical data from CORAL-1, the company's multi-center, dose escalation Phase 1 study evaluating KB407 in patients with cystic fibrosis. The clinical update will focus on results from patients in the highest dose cohort of the trial.
Study Design and Molecular Assessments
The interim clinical update will include molecular assessments of KB407 transduction and wild-type cystic fibrosis transmembrane conductance regulator (CFTR (搜索)) protein expression following inhaled administration of KB407. The CORAL-1 study represents a dose escalation Phase 1 trial designed to evaluate the investigational gene therapy in cystic fibrosis patients.
Company Background and Pipeline
Krystal Biotech is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company's first commercial product, VYJUVEK®, is the first-ever redosable gene therapy and the first genetic medicine approved in the United States, Europe, and Japan for the treatment of dystrophic epidermolysis bullosa.
The company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania.
Investor Access
Investors and the general public can access the live webcast through the company's designated platform. For those unable to listen to the live webcast, an archived version will be available on the Investors section of the company's website for at least 30 days following the presentation.